ObsEva
ObsEva [NASDAQ: OBSV; SIX: OBSN] is a Swiss-based, specialty biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva was founded in 2012 by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a clinician specialized in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. He was previously Co-Founder and CEO of PregLem. André Chollet is a medicinal and pharmaceutical chemist with over 30 years of experience gained in diverse roles within the biopharmaceutical industry, including at Biogen, GSK and Merck Serono.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Exit
Website
www.obseva.com
Related News
ObsEva SA Announces Pricing of Initial Public Offering
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
ObsEva Announces Results of the IMPLANT Phase 2 Trial of OBE001 (nolasiban) for the Improvement of Pregnancy and Live Birth Rates Following IVF/ICSI
ObsEva Closes CHF 60 (USD 60) Million in Series B Financing
ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.